Basking Biosciences Inc

basking is developing the first in class agent (bb-031) targeting von willebrand factor (vwf) along with a direct acting reversal agent (bb-025) to immediately the pharmacological effect of bb-031 in the event of bleeding. bb-031 is an rna aptamer optimized for rapid onset of action and short duration of effect. basking will initiate a phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. the technology is based on two decades of translational research on rna aptamers as therapeutic agents for cardiovascular diseases.